Security
Seaport Therapeutics, Inc. Common Stock · SPTX
SPTXNASDAQCommon stockCurrentCIK 2042347Updated Oct 6, 2026
SPTX price & chart
Loading TradingView…
NASDAQ:SPTX on TradingView ↗About the company
We are a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. Through our differentiated approach, we identify clinically validated mechanisms with established efficacy and safety profiles which had historically been limited by high first-pass metabolism, low bioavailability, and/or side effects. We apply our proprietary GlyphTM platform to overcome those limitations and invent innovative oral therapies. Glyph is a lymphatic-targeting prodrug technology which is designed to bypass first-pass metabolism and thereby enhance a drug’s oral bioavailability and reduce side effects. This process, which we call “Glyphing,” also creates new composition of matter intellectual property. Our experienced team of industry leaders has a proven track record in neuropsychiatry drug discovery and development and delivering successful business outcomes. We aim to develop novel, leading treatment options that will make a significant impact for patients and their families.
In the news
No coverage from other publishers is available.
Seeking Alpha
Seaport Therapeutics, Inc. (SPTX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript ↗
THQ Offers High-Yield Income From Healthcare Stocks (Rating Upgrade) ↗
SEC disclosures
Seaport Therapeutics, Inc. files 8-K: Material Event ↗
Recent filings
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
SCHEDULE 13G - filed by PureTech LYT, Inc. regarding Seaport Therapeutics, Inc.
SCHEDULE 13G - filed by Zohar Daphne regarding Seaport Therapeutics, Inc.
SCHEDULE 13G - filed by PAUL STEVEN M regarding Seaport Therapeutics, Inc.
Show 5 more recent filings
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
4 filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Offerings
Registration 333-294976
- Gross proceeds
- 254880000.0
- Net proceeds
- 237038400.0
- Deal price
- 18.0
- Shares
- 14160000
- Offering price
- $18.00
- Ticker
- SPTX
Underwriters: Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Leerink Partners LLC, Citigroup Global Markets Inc., Stifel, Nicolaus & Company, Incorporated
Registration 333-295477
Filing attachments
sptx-ex99_1.htm · 8-K · 2026-11-02
Exhibit 99.1 Seaport Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress Announced positive topline data from Phase 1 driving simulation trial of GlyphAlloTM, showing that GlyphAllo did not impair next-morning driving performance compared to placebo Dosed first patient in Phase 2a trial of GlyphAgoTM in patients with generalized anxiety disorder (GAD) and sleep disturbance; Company expects to initiate Phase 2/3 trial of GlyphAgo in p…
Read attachment ↗sptx-ex99_1.htm · 8-K · 2026-08-03
EX-99.1 2 sptx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress Enrollment in Phase 2b BUOY-1 trial of GlyphAlloTM in major depressive disorder (MDD) is on track with topline data expected in 1H 2027 Phase 1 driving simulation trial of GlyphAllo on track to report topline data in 2H 2026 Following positive data from completed Phase 1 proof-of-concept trial of GlyphAgoTM, Compa…
Read attachment ↗sptx-ex99_1.htm · 8-K · 2026-06-08
EX-99.1 2 sptx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress New data from Phase 1 trial of GlyphAgoTM build upon previously reported topline data and further demonstrate GlyphAgoTM can achieve therapeutic exposures of agomelatine at doses projected to avoid liver enzyme elevations and reduce or eliminate the need for liver function testing Enrollment in Phase 2b BUOY-1 trial…
Read attachment ↗d73463dex107.htm · S-1 · 2026-04-10
EX-10.7 10 d73463dex107.htm EX-10.7 EX-10.7 Exhibit 10.7 SEAPORT THERAPEUTICS, INC. EXECUTIVE SEVERANCE PLAN AND SUMMARY PLAN DESCRIPTION 1. Introduction and Purpose This document serves as the Plan document and Summary Plan Description (“SPD”) for the severance pay and benefits provided under the Seaport Therapeutics, Inc. Executive Severance Plan (the “Plan”). Seaport Therapeutics, Inc., a Delaware corporation (including its successors, the “Company”), considers it essential to foste…
Read attachment ↗d73463dex41.htm · S-1 · 2026-04-10
EX-4.1 4 d73463dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 . ZQ|CERT#|COY|CLS|RGSTRY|ACCT#|TRANSTYPE|RUN#|TRANS# COMMON STOCK COMMON STOCK PO PAR VALUE $.01 MR ADDADDADDADD 43 21A Box DESIGNATIONSAMPLE 43004, Certificate Shares (IF Number ** 000000 ****************** ANY) ZQ00000000 *** 000000 ***************** **** 000000 **************** Providence ***** 000000 *************** RI Seaport Therapeutics, Inc. ****** 000000 ************** INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE 02940 **…
Read attachment ↗d73463dex42.htm · S-1 · 2026-04-10
EX-4.2 5 d73463dex42.htm EX-4.2 EX-4.2 Exhibit 4.2 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL, AND THE REGISTRANT TREATS SUCH INFORMATION AS PRIVATE AND CONFIDENTIAL. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of October 18, 2024, by and among Seaport Therapeutics, Inc., a Delaware corporation (the…
Read attachment ↗